Variability of 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute leukemia
作者： Olle Björk , Curt Peterson , Lars Åhström , Salah Hayder , Pierre Lafolie
DOI: 10.1007/BF02985158
关键词:
摘要: The effects of some environmental and genetic factors on the inter- intraindividual variations 6-mercaptopurine (6-MP) pharmacokinetics were studied in children oral remission maintenance therapy for acute lymphoblastic leukemia or non-Hodgkin’s lymphoma. Blood samples obtained 0–4 h after drug intake. 6-MP concentrations determined plasma erythrocyte concentrates. influence food was examined a prospective study 15 children. Each child four times, twice fasted state intake standardized, milky, breakfast. There pronounced variations. Food seemed to reduce these but there no significant changes peak area under concentration vs time curves (AUC) between fed states. reduced both plasma, from 1.8 1.1 (P 70 mg m−2 had higher AUC fasting state, while five out eight patients receiving <70 state. cytochrome P-450-dependent hydroxylation capacity evaluated with debrisoquine correlation found 6-MP.
springer.com
sci-hub.se 参考文章(40)
J. H. BURCHENAL, M. L. MURPHY, R. R. ELLISON, M. P. SYKES, T. C. TAN, L. A. LEONE, D. A. KARNOF-SKY, L. F. CRAVER, H. W. DARGEON, C. P. RHOADS, Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood. ,vol. 8, pp. 965- 999 ,(1953) , 10.1182/BLOOD.V8.11.965.965
David G. Poplack, Lawrence J. Ettinger, Solomon Zimm, Jean Belasco, Barton A. Kamen, Jerry M. Collins, Lawrence E. Lavi, Teresa J. Vietti, Nancy Cogliano-Shutta, John S. Holcenberg, Frank Balis, Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. Cancer Research. ,vol. 45, pp. 1869- 1873 ,(1985)
Alan R. P. Paterson, David M. Tidd, A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Research. ,vol. 34, pp. 738- 746 ,(1974)
Neal S. Leleiko, Beth A. Martin, Martin Walsh, Philip Kazlow, Simon Rabinowitz, Kenneth Sterling, Tissue-specific gene expression results from a purine- and pyrimidine-free diet and 6-mercaptopurine in the rat small intestine and colon Gastroenterology. ,vol. 93, pp. 1014- 1020 ,(1987) , 10.1016/0016-5085(87)90564-6
R M Weinshilboum, J A Van Loon, Human lymphocyte thiopurine methyltransferase pharmacogenetics: effect of phenotype on 6-mercaptopurine-induced inhibition of mitogen stimulation. Journal of Pharmacology and Experimental Therapeutics. ,vol. 242, pp. 21- 26 ,(1987)
Solomon Zimm, John J. Grygiel, John M. Strong, Terrence J. Monks, David G. Poplack, Identification of 6-mercaptopurine riboside in patients receiving 6-mercaptopurine as a prolonged intravenous infusion Biochemical Pharmacology. ,vol. 33, pp. 4089- 4092 ,(1984) , 10.1016/0006-2952(84)90026-1
Gertrude B. Elion, Sandra Callahan, Henry Nathan, Samuel Bieber, R.Wayne Rundles, George H. Hitchings, Potentiation by inhibition of drug degradation : 6-substituted purines and xanthine oxidase Biochemical Pharmacology. ,vol. 12, pp. 85- 93 ,(1963) , 10.1016/0006-2952(63)90012-1
W. Kalow, Genetics of drug transformation. Clinical Biochemistry. ,vol. 19, pp. 76- 82 ,(1986) , 10.1016/S0009-9120(86)80052-2
Neil K. Burton, Michael J. Barnett, G. Wynne Aherne, Julienne Evans, Ian Douglas, T. Andrew Lister, The effect of food on the oral administration of 6-mercaptopurine Cancer Chemotherapy and Pharmacology. ,vol. 18, pp. 90- 91 ,(1986) , 10.1007/BF00253074
Larry A. Bauer, Milo Gibaldi, Robert E. Vestal, Influence of Pharmacokinetic Diurnal Variation on Bioavailability Estimates Clinical Pharmacokinectics. ,vol. 9, pp. 184- 187 ,(1984) , 10.2165/00003088-198409020-00006